238 related articles for article (PubMed ID: 29464673)
21. Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis.
Chiao E; Meyer K
Curr Med Res Opin; 2009 Jun; 25(6):1445-54. PubMed ID: 19422279
[TBL] [Abstract][Full Text] [Related]
22. Health economic outcomes of switching to alemtuzumab from other disease-modifying therapies in people with multiple sclerosis in the USA.
Araujo L; Kyatham S; Bzdek KG; Higuchi K; Greene N
J Comp Eff Res; 2023 Jan; 12(1):e220127. PubMed ID: 36440609
[No Abstract] [Full Text] [Related]
23. Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis.
Freedman MS; Montalban X; Miller AE; Dive-Pouletty C; Hass S; Thangavelu K; Leist TP
Mult Scler Relat Disord; 2016 Nov; 10():204-212. PubMed ID: 27919491
[TBL] [Abstract][Full Text] [Related]
24. Patterns of disease-modifying therapy utilization before, during, and after pregnancy and postpartum relapses in women with multiple sclerosis.
Bove R; Applebee A; Bawden K; Fine C; Shah A; Avila RL; Belviso N; Branco F; Fong K; Lewin JB; Liu J; England SM; Vignos M
Mult Scler Relat Disord; 2024 Jun; 88():105738. PubMed ID: 38959591
[TBL] [Abstract][Full Text] [Related]
25. Cost of care according to disease-modifying therapy in Mexicans with relapsing-remitting multiple sclerosis.
Macías-Islas MA; Soria-Cedillo IF; Velazquez-Quintana M; Rivera VM; Baca-Muro VI; Lemus-Carmona EA; Chiquete E
Acta Neurol Belg; 2013 Dec; 113(4):415-20. PubMed ID: 23670405
[TBL] [Abstract][Full Text] [Related]
26. Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: a retrospective US claims database analysis.
Bergvall N; Makin C; Lahoz R; Agashivala N; Pradhan A; Capkun G; Petrilla A; Karkare SU; Balderston McGuiness C; Korn JR
Curr Med Res Opin; 2013 Dec; 29(12):1647-56. PubMed ID: 24059944
[TBL] [Abstract][Full Text] [Related]
27. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
[TBL] [Abstract][Full Text] [Related]
28. Treatment Patterns, Healthcare Resource Utilization, and Costs Among Medicare Patients with Multiple Sclerosis in Relation to Disease-Modifying Therapy and Corticosteroid Treatment.
Sanchirico M; Caldwell-Tarr A; Mudumby P; Hashemi L; Dufour R
Neurol Ther; 2019 Jun; 8(1):121-133. PubMed ID: 30565050
[TBL] [Abstract][Full Text] [Related]
29. Evaluating Treatment Patterns, Relapses, Healthcare Resource Utilization, and Costs Associated with Disease-Modifying Treatments for Multiple Sclerosis in DMT-Naïve Patients.
Freeman L; Kee A; Tian M; Mehta R
Clinicoecon Outcomes Res; 2021; 13():65-75. PubMed ID: 33519217
[TBL] [Abstract][Full Text] [Related]
30. Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis.
Halpern R; Agarwal S; Dembek C; Borton L; Lopez-Bresnahan M
Patient Prefer Adherence; 2011 Jan; 5():73-84. PubMed ID: 21423591
[TBL] [Abstract][Full Text] [Related]
31. Teriflunomide for multiple sclerosis.
He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
[TBL] [Abstract][Full Text] [Related]
32. Treatment patterns in multiple sclerosis: administrative claims analysis over 10 years.
Oleen-Burkey M; Cyhaniuk A; Swallow E
J Med Econ; 2013; 16(3):397-406. PubMed ID: 23301877
[TBL] [Abstract][Full Text] [Related]
33. Use and safety of disease-modifying therapy in pregnant women with multiple sclerosis.
MacDonald SC; McElrath TF; Hernández-Díaz S
Pharmacoepidemiol Drug Saf; 2019 Apr; 28(4):556-560. PubMed ID: 30834654
[TBL] [Abstract][Full Text] [Related]
34. Initiation Patterns of Disease-Modifying Therapies for Multiple Sclerosis Among US Adults and Children, 2001 Through 2020.
Henderson M; Horton DB; Bhise V; Pal G; Bushnell G; Dave CV
JAMA Neurol; 2023 Aug; 80(8):860-867. PubMed ID: 37428482
[TBL] [Abstract][Full Text] [Related]
35. Real-World Clinical and Economic Outcomes Among Persons With Multiple Sclerosis Initiating First- Versus Second- or Later-Line Treatment With Ocrelizumab.
Geiger CK; Sheinson D; To TM; Jones D; Bonine NG
Neurol Ther; 2023 Oct; 12(5):1709-1728. PubMed ID: 37458897
[TBL] [Abstract][Full Text] [Related]
36. Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry.
Braune S; Grimm S; van Hövell P; Freudensprung U; Pellegrini F; Hyde R; Bergmann A;
J Neurol; 2018 Dec; 265(12):2980-2992. PubMed ID: 30327931
[TBL] [Abstract][Full Text] [Related]
37. The impact of diagnostic criteria and treatments on the 20-year costs for treating relapsing-remitting multiple sclerosis.
Petruzzo M; Palladino R; Nardone A; Nozzolillo A; Servillo G; Orlando V; De Angelis M; Lanzillo R; Brescia Morra V; Moccia M
Mult Scler Relat Disord; 2020 Feb; 38():101514. PubMed ID: 31759185
[TBL] [Abstract][Full Text] [Related]
38. Resource utilization, costs and treatment patterns of switching and discontinuing treatment of MS patients with high relapse activity.
Raimundo K; Tian H; Zhou H; Zhang X; Kahler KH; Agashivala N; Kim E
BMC Health Serv Res; 2013 Apr; 13():131. PubMed ID: 23565628
[TBL] [Abstract][Full Text] [Related]
39. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935
[TBL] [Abstract][Full Text] [Related]
40. Medication adherence with disease modifying treatments for multiple sclerosis among US employees.
Kleinman NL; Beren IA; Rajagopalan K; Brook RA
J Med Econ; 2010; 13(4):633-40. PubMed ID: 20958113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
